According to Fortune Business Insights, the global Gallbladder Cancer Treatment Market size was valued at USD 908.0 million in 2025. The market is projected to grow from USD 1,028.0 million in 2026 to USD 2,287.0 million by 2034, exhibiting a CAGR of 10.51% during the forecast period 2026–2034. Asia Pacific dominated the market in 2025, accounting for a 36.08% market share. The market is expanding as gallbladder cancer is frequently diagnosed at an advanced stage, increasing the need for systemic treatment options such as chemotherapy, immunotherapy, targeted therapy, and combination regimens.

Market Overview

The Gallbladder Cancer Treatment Market includes therapies administered across different stages and treatment settings. Key drugs covered by the market include gemcitabine, cisplatin, durvalumab, pembrolizumab, capecitabine, oxaliplatin, fluorouracil, zanidatamab, and trastuzumab deruxtecan.

The market is characterized by continued reliance on conventional chemotherapy alongside the growing adoption of immunotherapy and targeted therapy. Gemcitabine and cisplatin remain important components of treatment for unresectable and metastatic disease, while the addition of immune checkpoint inhibitors is expanding first-line treatment options.

The market is segmented by drug, drug class, therapy, route of administration, age group, distribution channel, and region.

For detailed market insights: https://www.fortunebusinessinsights.com/industry-reports/gallbladder-cancer-treatment-market-101001

Market Trends

Increasing Pharmaceutical Investment in Advanced Cancer Treatments

Increasing pharmaceutical investment in rare and advanced cancers is a prominent trend in the market. The relatively small patient population, aggressive disease progression, late diagnosis, and limited treatment alternatives are encouraging pharmaceutical companies to develop therapies applicable to broader biliary tract cancer populations.

Companies are evaluating targeted antibodies, immunotherapy combinations, novel drug-delivery systems, and biomarker-based treatments. Regulatory support for therapies addressing serious and rare diseases is also encouraging continued clinical development.

For example, in July 2025, FUJIFILM Pharmaceuticals U.S.A. received orphan drug designation from the U.S. FDA for FF-10832, an investigational liposomal formulation of gemcitabine for biliary tract cancer.

Market Drivers

Expansion of First-line Chemo-Immunotherapy

The increasing use of chemo-immunotherapy as a first-line treatment is a major factor driving market growth. Patients with unresectable, locally advanced, or metastatic gallbladder cancer have traditionally relied on gemcitabine- and cisplatin-based chemotherapy.

The addition of immune checkpoint inhibitors to chemotherapy can strengthen the antitumor immune response and improve survival compared with chemotherapy alone. As these combination regimens become integrated into treatment guidelines and adopted across more countries, immunotherapy utilization is expected to increase.

The rising global cancer burden, expansion of approved biosimilar portfolios, price discounts, institutional reimbursement frameworks, and future loss of exclusivity for checkpoint inhibitors are also identified as factors influencing market growth.

However, low disease incidence and frequent late-stage diagnosis restrict the commercially addressable patient population. The source notes that only around 10%–20% of patients may be eligible for curative surgical resection at diagnosis, further limiting the treatment pool.

Market Segmentation

By Drug

Based on drug, the market is segmented into gemcitabine, cisplatin, durvalumab, pembrolizumab, capecitabine, oxaliplatin, fluorouracil, zanidatamab, trastuzumab deruxtecan, and others.

The durvalumab segment dominated the market due to its established use with gemcitabine and cisplatin in previously untreated, locally advanced, or metastatic biliary tract cancer. Its early regulatory entry provided a first-mover advantage in first-line chemo-immunotherapy. Meanwhile, the pembrolizumab segment is projected to grow at a 13.29% CAGR during the forecast period.

By Drug Class

The market is categorized into antimetabolites, platinum compounds, PD-1 inhibitors, PD-L1 inhibitors, bispecific antibodies, antibody-drug conjugates, topoisomerase inhibitors, taxanes, and others.

Antimetabolites dominated in 2025, supported by the extensive use of gemcitabine. Its continued inclusion in chemo-immunotherapy regimens involving durvalumab and pembrolizumab further strengthens the segment. The PD-1 inhibitors segment is projected to grow at a 13.29% CAGR.

By Therapy

Based on therapy, the market is segmented into chemotherapy, immunotherapy, targeted therapy, and others.

Chemotherapy dominated the market in 2025 because it remains a central treatment option for patients who are not eligible for curative surgery or whose disease has progressed. Gemcitabine and cisplatin remain widely used, while capecitabine and fluorouracil can be used in adjuvant or alternative settings. The immunotherapy segment is projected to grow at an 11.35% CAGR.

By Route of Administration

The market is divided into parenteral and oral routes. The parenteral segment accounted for the largest share in 2025, as many major therapies, including gemcitabine, cisplatin, durvalumab, pembrolizumab, zanidatamab, and trastuzumab deruxtecan, are primarily administered through infusion. The oral segment is projected to grow at a 9.46% CAGR.

By Age Group and Distribution Channel

By age group, the market is divided into adults and pediatric patients. The adults segment dominated in 2025, supported by higher disease incidence and greater availability of approved treatments. The pediatric segment is projected to grow at a 7.43% CAGR.

By distribution channel, the market includes hospital pharmacies, specialty pharmacies, drug stores and retail pharmacies, and online pharmacies. Hospital pharmacies dominated in 2025, while online pharmacies are projected to record a 17.54% CAGR during the forecast period.

Key Players

Major companies operating in the Gallbladder Cancer Treatment Market include AstraZeneca plc, Merck & Co., Inc., Pfizer Inc., Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Hikma Pharmaceuticals PLC, Accord Healthcare, Sun Pharmaceutical Industries Ltd., Eli Lilly and Company, and Dr. Reddy’s Laboratories Ltd.

Regional Analysis

Asia Pacific dominated the global market in 2025, accounting for a 36.08% share, and is estimated to reach USD 376.4 million in 2026. The region's comparatively high gallbladder cancer burden, improving diagnosis, healthcare infrastructure, and access to chemotherapy, immunotherapy, and targeted therapies support growth.

China's market is estimated at USD 114.3 million in 2026, while Japan is expected to reach approximately USD 78.5 million and India approximately USD 74.5 million.

North America held the second position in 2025, with a market value of USD 277.6 million. Increasing adoption of first-line chemo-immunotherapy and molecular testing is supporting regional development.

Europe is projected to grow at an 8.22% CAGR, supported by regulatory approvals and reimbursement of immunotherapy-based combinations. Latin America is expected to witness significant growth, while the Middle East & Africa market is supported by increasing cancer detection and specialist oncology services.

Competitive Landscape

The competitive landscape is shaped by global oncology companies, generic injectable manufacturers, and regional pharmaceutical suppliers. Companies are strengthening their portfolios through regulatory approvals, geographic expansion, first-line combination studies, new formulations, and strategic partnerships.

Major companies such as AstraZeneca, Merck & Co., Jazz Pharmaceuticals, Daiichi Sankyo, Roche, and Eli Lilly are competing through product innovation, clinical development, generic availability, partnerships, and geographic expansion.

Strategic collaborations are also helping companies accelerate geographic expansion. In July 2025, Zymeworks collaborated with Jazz Pharmaceuticals and BeOne Medicines for the development and commercialization of zanidatamab across different global territories.

Future Outlook

The Gallbladder Cancer Treatment Market is expected to experience strong growth through 2034 as pharmaceutical companies expand investment in advanced cancer therapies. The movement of targeted therapies into earlier treatment lines represents a significant opportunity because earlier intervention could expand the eligible patient population and increase treatment duration.

HER2-targeted therapies, biomarker testing, companion diagnostics, immune checkpoint inhibitors, bispecific antibodies, and antibody-drug conjugates are expected to remain important areas of development. Successful clinical trials and regulatory approvals could broaden treatment indications and create additional opportunities for market participants.

At the same time, the small and geographically concentrated patient population will remain a challenge for clinical development. Multinational trials may be required to recruit sufficient biomarker-eligible patients, increasing development complexity and costs.

Get a free sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/gallbladder-cancer-treatment-market-101001

Conclusion

The Gallbladder Cancer Treatment Market is projected to grow from USD 1,028.0 million in 2026 to USD 2,287.0 million by 2034, registering a 10.51% CAGR. The market's growth is being supported by the expansion of first-line chemo-immunotherapy, increasing pharmaceutical investment, biomarker-based treatment, and the development of targeted therapies.

Asia Pacific remains the leading regional market, while durvalumab, antimetabolites, chemotherapy, parenteral therapies, adults, and hospital pharmacies held leading positions across their respective segments in 2025. Going forward, targeted therapies, immunotherapy combinations, molecular profiling, and earlier-line treatment applications are expected to shape the market's development.

Frequently Asked Questions

1. What is the size of the Gallbladder Cancer Treatment Market in 2025?

According to Fortune Business Insights, the global Gallbladder Cancer Treatment Market was valued at USD 908.0 million in 2025.

2. What will be the Gallbladder Cancer Treatment Market size by 2034?

The market is projected to reach USD 2,287.0 million by 2034, increasing from USD 1,028.0 million in 2026.

3. What is the CAGR of the Gallbladder Cancer Treatment Market?

The market is expected to grow at a CAGR of 10.51% during 2026–2034.

4. Which drug segment is expected to lead the Gallbladder Cancer Treatment Market?

The durvalumab segment dominated the market, supported by its established use with gemcitabine and cisplatin in first-line treatment of advanced biliary tract cancer, including gallbladder cancer.

5. Which region dominated the Gallbladder Cancer Treatment Market in 2025?

Asia Pacific dominated the market in 2025, accounting for a 36.08% share of the global market. The region's comparatively high disease burden and improving access to advanced cancer treatments support its leading position.

Curious About Japan’s Market? Explore the Latest Gallbladder Cancer Treatment Market Insights